Financial
Latest full-year results from official filings.
FY2025 revenue $6.07bn (+11.5%); operating margin 20.8%; net income $1.06bn.
Cash $3.00bn; debt $600.0m.
- Official results release · Edwards Lifesciences · 31 Dec 2025
Edwards Lifesciences: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Jan 2026: A US federal court granted the FTC an injunction blocking Edwards' planned acquisition of JenaValve, and Edwards abandoned the deal; the company said it disagreed with the decision.
- Edwards' JenaValve acquisition nixed as FTC injunction approved by court · Medical Device Network (via Yahoo Finance) · 12 Jan 2026
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No company-confirmed or reputably reported data breaches, cyber incidents or regulator actions involving Edwards Lifesciences found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Jul 2025: Edwards recalled OptiSite and certain femoral arterial cannulae after wire was found exposed at the cannula tip; FDA classed it as the most serious recall type. No serious injuries or deaths had been reported as of May 2025.
- Arterial Cannula Recall: Edwards Lifesciences Removes Arterial Cannula Due to Risk of Wire Exposure · US FDA · 24 Jul 2025
Contract performance
Contract delivery, go-lives, terminations and disputes.
No contract terminations, customer disputes or significant NHS contract news involving Edwards Lifesciences found in HSH's search of the last 24 months.